JP2008505143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008505143A5 JP2008505143A5 JP2007519679A JP2007519679A JP2008505143A5 JP 2008505143 A5 JP2008505143 A5 JP 2008505143A5 JP 2007519679 A JP2007519679 A JP 2007519679A JP 2007519679 A JP2007519679 A JP 2007519679A JP 2008505143 A5 JP2008505143 A5 JP 2008505143A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- kit according
- antibody
- antigen
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 10
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 7
- 238000002271 resection Methods 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 3
- 210000001165 lymph node Anatomy 0.000 claims 3
- 206010009253 Clear cell sarcoma of the kidney Diseases 0.000 claims 2
- 208000030748 clear cell sarcoma of kidney Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 101100282617 Bovine herpesvirus 1.1 (strain Cooper) gC gene Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000000683 nonmetastatic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58467904P | 2004-07-02 | 2004-07-02 | |
| PCT/EP2005/006994 WO2006002889A2 (en) | 2004-07-02 | 2005-06-29 | Improved adjuvant therapy of g250-expressing tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008505143A JP2008505143A (ja) | 2008-02-21 |
| JP2008505143A5 true JP2008505143A5 (https=) | 2008-05-29 |
Family
ID=35431139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007519679A Pending JP2008505143A (ja) | 2004-07-02 | 2005-06-29 | Ｇ２５０発現腫瘍の改善されたアジュバント療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7691375B2 (https=) |
| EP (2) | EP1763367A2 (https=) |
| JP (1) | JP2008505143A (https=) |
| KR (1) | KR101205289B1 (https=) |
| CN (1) | CN101052416B (https=) |
| AU (1) | AU2005259481B2 (https=) |
| BR (1) | BRPI0512854A (https=) |
| CA (1) | CA2566950A1 (https=) |
| DK (1) | DK2497497T3 (https=) |
| ES (1) | ES2641089T3 (https=) |
| MX (1) | MXPA06013240A (https=) |
| RU (2) | RU2371198C2 (https=) |
| WO (1) | WO2006002889A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077081A1 (en) * | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| US7632496B2 (en) * | 2002-07-01 | 2009-12-15 | Wilex Ag | Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas |
| KR20120082429A (ko) | 2009-09-18 | 2012-07-23 | 미쓰비시 가가꾸 가부시키가이샤 | 간세포암 마커 |
| RU2442983C1 (ru) * | 2011-01-14 | 2012-02-20 | Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| BR112015020061A8 (pt) * | 2013-02-22 | 2018-01-23 | Wilex Ag | composto alvo anidrase carbônica ix (caix) para tratamento de câncer, seus usos, composição farmcêutica, e método para diagnosticar, prognosticar e/ou classificar um câncer |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| EP3525829A1 (en) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0366707A1 (en) * | 1987-05-06 | 1990-05-09 | OOSTERWIJK, Egbert | Monoclonal antibodies to renal cell carcinoma |
| US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
| US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| DK1733736T3 (en) * | 2001-02-07 | 2015-06-01 | Wilex Ag | A process for the production of recombinant antibodies to tumors |
| JP2006500905A (ja) * | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| US7632496B2 (en) * | 2002-07-01 | 2009-12-15 | Wilex Ag | Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas |
| RU2257200C1 (ru) * | 2004-05-12 | 2005-07-27 | Кутушов Михаил Владимирович | Лекарственное средство |
-
2005
- 2005-06-29 KR KR1020067027704A patent/KR101205289B1/ko not_active Expired - Fee Related
- 2005-06-29 RU RU2007104040/14A patent/RU2371198C2/ru not_active IP Right Cessation
- 2005-06-29 US US11/630,170 patent/US7691375B2/en not_active Expired - Lifetime
- 2005-06-29 CA CA002566950A patent/CA2566950A1/en not_active Abandoned
- 2005-06-29 DK DK12171081.8T patent/DK2497497T3/en active
- 2005-06-29 MX MXPA06013240A patent/MXPA06013240A/es active IP Right Grant
- 2005-06-29 ES ES12171081.8T patent/ES2641089T3/es not_active Expired - Lifetime
- 2005-06-29 BR BRPI0512854-4A patent/BRPI0512854A/pt not_active Application Discontinuation
- 2005-06-29 WO PCT/EP2005/006994 patent/WO2006002889A2/en not_active Ceased
- 2005-06-29 EP EP05775970A patent/EP1763367A2/en not_active Ceased
- 2005-06-29 CN CN2005800205034A patent/CN101052416B/zh not_active Expired - Fee Related
- 2005-06-29 AU AU2005259481A patent/AU2005259481B2/en not_active Expired
- 2005-06-29 EP EP12171081.8A patent/EP2497497B1/en not_active Expired - Lifetime
- 2005-06-29 JP JP2007519679A patent/JP2008505143A/ja active Pending
-
2009
- 2009-06-10 RU RU2009122344/15A patent/RU2519340C2/ru not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009122344A (ru) | Улучшенная вспомогательная терапия опухолей, экспрессирующих g250 | |
| JP2008505143A5 (https=) | ||
| JP2021515566A5 (https=) | ||
| JP5992843B2 (ja) | 抗ＩＬ−１α抗体による癌の処置方法 | |
| BR112021000353A2 (pt) | inibidores de tgfb1 de alta afinidade, isoforma-seletivos, e seus usos | |
| TW201808330A (zh) | 藉由投予ｐｄ－１抑制劑治療皮膚癌之方法 | |
| JP2017522861A5 (https=) | ||
| JP2022512750A5 (https=) | ||
| RU2017127772A (ru) | Человеческие антитела к токсинам clostridium difficile | |
| JP2015509962A5 (https=) | ||
| JP2011006464A (ja) | 喘息の治療における抗−ＴＮＦα抗体 | |
| ES2891336T3 (es) | Combinaciones y usos de las mismas | |
| JP2020533965A5 (https=) | ||
| JP2020522280A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| JP2018512402A5 (https=) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2020531003A5 (https=) | ||
| US11274154B2 (en) | Dosing regimen of avelumab for the treatment of cancer | |
| JP2025509567A5 (https=) | ||
| JP2022044827A (ja) | 免疫媒介性がん治療のための組成物及び方法 | |
| CN117427186A (zh) | 抗her2抗体药物偶联物联合抗pd-l1抗体在制备治疗肺癌的药物中的用途 | |
| US20240009275A1 (en) | Combination immunotherapy of il-15 and cd40 agonist in cancer treatment | |
| TWI619728B (zh) | Ｇｉｓｔ之治療 | |
| US11623003B2 (en) | Vaccination against diabetes, obesity and complications thereof |